Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
暂无分享,去创建一个
C. Kensil | M. Powell | J. Y. Wu | M. Newman | B. Gardner | J. Recchia | C. Anderson | R. Coughlin
[1] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[2] G. Shaw,et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.
[3] C. Kensil,et al. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. , 1994, AIDS research and human retroviruses.
[4] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[5] R. Siliciano,et al. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine , 1994, Journal of virology.
[6] J. Y. Wu,et al. Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphocyte assays. , 1994, Clinical and diagnostic laboratory immunology.
[7] M. Kieny,et al. Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1Lai is more commonly recognized than HIV-1MN. , 1994, The Journal of infectious diseases.
[8] D. Ho,et al. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope , 1994, The Journal of experimental medicine.
[9] N. Roberts,et al. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. , 1993, The Journal of infectious diseases.
[10] S. Chang,et al. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes , 1993, Journal of virology.
[11] M. McElrath,et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Walker,et al. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone , 1993, Journal of virology.
[13] R. Siliciano,et al. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV- 1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines , 1992, The Journal of experimental medicine.
[14] M. Champe,et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 , 1992, Journal of virology.
[15] J. Levy,et al. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. , 1992, AIDS research and human retroviruses.
[16] B. Walker,et al. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation , 1992, The Journal of experimental medicine.
[17] C. Kensil,et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. , 1992, Journal of immunology.
[18] R A Houghten,et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. , 1992, Science.
[19] B. Haynes,et al. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Berzofsky,et al. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. , 1991, The Journal of clinical investigation.
[21] S. Chada,et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. , 1991, AIDS research and human retroviruses.
[22] J. Berzofsky,et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. , 1991, Journal of immunology.
[23] C. Kensil,et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.
[24] D. Nixon,et al. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. , 1990, International immunology.
[25] M. McGrath,et al. Effects of GLQ223 on HIV replication in human monocyte/macrophages chronically infected in vitro with HIV. , 1990, AIDS research and human retroviruses.
[26] T. Masuda,et al. Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro , 1990, Journal of virology.
[27] B. Walker,et al. Techniques in HIV Research , 1990, Palgrave Macmillan UK.
[28] J. Berzofsky,et al. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.
[29] G. Gaudernack,et al. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. , 1990, Journal of immunology.
[30] J. Berzofsky,et al. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself , 1990, The Journal of experimental medicine.
[31] J. Berzofsky,et al. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. , 1989, Science.
[32] C. DeLisi,et al. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. , 1989, International immunology.
[33] G. Nakamura,et al. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160 , 1989, Journal of virology.
[34] E. Lennette,et al. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections , 1989 .
[35] J. Berzofsky,et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals , 1989, Nature.
[36] B. Autran,et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. , 1989, Journal of immunology.
[37] P. Earl,et al. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[38] C. DeLisi,et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[39] B. Walker,et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. , 1988, Science.
[40] B. Walker,et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.
[41] J. Levy,et al. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.
[42] R. Siliciano,et al. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. , 1994, AIDS research and human retroviruses.
[43] A. Burny,et al. Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual. , 1994, AIDS research and human retroviruses.
[44] B. Walker,et al. Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. , 1994, Current topics in microbiology and immunology.
[45] C. Czerkinsky,et al. Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides. , 1993, Vaccine.
[46] F. Plata. Implications of HIV specific cytotoxic T lymphocytes in AIDS , 1992, Biotherapy.
[47] M. Popovič,et al. Virus Isolation and Production , 1990 .